High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure due to COVID-19: A Multicenter Phase 2 Trial
Description
CONCLUSIONS: The use of high-dose inhaled nitric oxide resulted in an improvement of PaO(2)/FiO(2) at 48h compared with usual care in adults with acute hypoxemic respiratory failure due to COVID-19. This article is open access and distributed under
